All In Biotech

BLA 761289 · Astrazeneca Ab

Imjudo

Tremelimumab-Actl · Intravenous · CTLA-4-directed Blocking Antibody

NovelPriority reviewOrphan

CDER novel approval, Oct 21, 2022: To treat unresectable hepatocellular carcinoma

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Oct 21, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

260

26 Phase 3, 38 recruiting

FAERS reports

4,428

4,294 serious, 1,275 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.2 ) 1.1 Hepatocellular Carcinoma IMJUDO, in combination with durvalumab, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.2 Non-Small Cell Lung Cancer (NSCLC) IMJUDO, in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Mechanism: CTLA-4 is a negative regulator of T-cell activity. Tremelimumab-actl is a monoclonal antibody that binds to CTLA-4 and blocks the interaction with its ligands CD80 and CD86, releasing CTLA-4-mediated inhibition of T-cell activation. In synergistic mouse tumor models, blocking CTLA-4 activity resulted in decreased tumor growth and increased proliferation of T cells in tumors.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 21, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
  • IMJUDO · TREMELIMUMAB-ACTL 25MG/1.25ML(20MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
  • IMJUDO · TREMELIMUMAB-ACTL 300MG/15ML(20MG/ML) · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tremelimumab" as an intervention, any sponsor and status, largest first.

All 260 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death412
  • diarrhoea301
  • malignant neoplasm progression294
  • pyrexia228
  • colitis194
  • cytokine release syndrome175
  • immune-mediated enterocolitis159
  • rash151
  • liver disorder133
  • pneumonia124
  • pneumonitis103
  • myocarditis100

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20073
20086
20092
20121
20144
20157
201640
2017409
2018405
201986
2020106
202187
202276
2023516
2024966
2025966
2026748

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Imjudo (Tremelimumab-Actl)

2024 spending

$2.8M

Beneficiaries

70

81 claims

Per beneficiary

$39,362

$2,630.52 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$2,386,437
2024$2,755,354

Part B: Imjudo (Tremelimumab-Actl) · HCPCS J9347

2024 spending

$48.5M

Beneficiaries

1,259

1,718 claims

Per beneficiary

$38,527

2024 ASP limit $135.71 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$19,156,122
2024$48,504,943

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 239 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.